Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Goutam C. Mistry"'
Autor:
Gary A. Herman, Jon L. Ruckle, Ronald B. Langdon, Amy Qiu Wang, Keith Gottesdiener, Michael J. Davies, Bingming Yi, Goutam C. Mistry, John A. Wagner, Li Chen, Karen Snyder, Patrick Larson, Arthur J. Bergman, Wei Zeng
Publikováno v:
British Journal of Clinical Pharmacology. 71:429-436
AIMS Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. The present aim was to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety characteristics of sitagliptin following single doses in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42f08666375a5220048a0b3c7fa6d792
https://doi.org/10.1111/j.1365-2125.2010.03852.x
https://doi.org/10.1111/j.1365-2125.2010.03852.x
Autor:
John A. Wagner, Peng Sun, Julie A. Stone, Alisha Norcross, Paul J. Deutsch, Naoto Uemera, Wendy Comisar, Gregory A. Winchell, Sheng Bi, Goutam C. Mistry, Elizabeth Migoya, Kalyan Ghosh
Publikováno v:
The Journal of Clinical Pharmacology. 51:202-211
Caspofungin was the first in a new class of antifungal agents (echinocandins) indicated for the treatment of primary and refractory fungal infections. Higher doses of caspofungin may provide another option for patients who have failed caspofungin or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3a1d9cae99c131755657612de853ed
https://doi.org/10.1177/0091270010374853
https://doi.org/10.1177/0091270010374853
Autor:
Wei Zeng, John A. Wagner, Q Liu, Li Chen, Kenneth C. Lasseter, Amy Qiu Wang, Julie A. Stone, Rajesh Krishna, Arthur J. Bergman, Gary A. Herman, Goutam C. Mistry, Stacy C. Dilzer, Wen-Lin Luo
Publikováno v:
Biopharmaceutics & Drug Disposition. 28:307-313
Sitagliptin is a highly selective orally active dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. Ten healthy subjects received single oral doses of 25, 50, 100, 200 and 400 mg final market
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8002d922feef4d5ae69450b1e1713d74
https://doi.org/10.1002/bdd.559
https://doi.org/10.1002/bdd.559
Autor:
Brigitta U. Mueller, Seth M. Steinberg, Paul J. Deutsch, Steve Zeichner, John W. Sleasman, Paul Jarosinski, Sheryl Zwerski, Robert P. Nelson, Ju William D, Pim Brouwers, Gregory A. Winchell, Lauren V. Wood, Philip A. Pizzo, Frank M. Balis, Sharon R. Smith, Shizuko Sei, Goutam C. Mistry
Publikováno v:
Pediatrics. 102:101-109
Background. Indinavir, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, is approved for the treatment of HIV infection in adults when antiretroviral therapy is indicated. We evaluated the safety and pharmacokinetic profile of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f68e3389906b5317035bbdc71f5b031b
https://doi.org/10.1542/peds.102.1.101
https://doi.org/10.1542/peds.102.1.101
Autor:
Yang Xu, Anup K. Majumdar, Gary A. Herman, Susan M. Abdel-Rahman, Santiago Topelberg, Jeffrey L. Blumer, John A. Wagner, Michelle Groff, Chester J. Kitchen, Richard F. Jacobs, Gregory L. Kearns, Goutam C. Mistry
Publikováno v:
The Pediatric infectious disease journal. 29(12)
Ertapenem is a carbapenem antibiotic with broad spectrum activity and a pharmacokinetic profile that favors once-daily administration in adults.This investigation was designed to evaluate the dose-exposure profile of ertapenem in children from infanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26d74d902f276ea1e8e26f9b9667051
https://pubmed.ncbi.nlm.nih.gov/20571461
https://pubmed.ncbi.nlm.nih.gov/20571461
Autor:
Goutam C. Mistry, Sarah Y. Liou, Julie A. Stone, Amelia S. Petry, Maria J. Gutierrez, Neal Azrolan, Larissa Wenning, Kaylan Ghosh, William E. Bridson, Marian Iwamoto, Sheila Breidinger, John A. Wagner, Keith Gottesdiener
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 47(1)
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d60e884252e38cfac4d630d1a2d681e
https://pubmed.ncbi.nlm.nih.gov/18513146
https://pubmed.ncbi.nlm.nih.gov/18513146
Autor:
Michael J. Davies, Keith Gottesdiener, John A. Wagner, Goutam C. Mistry, Gary A. Herman, Andrea Maes, Kenneth C. Lasseter
Publikováno v:
Journal of clinical pharmacology. 48(5)
The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, 3-period crossover study. Nineteen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03b922c91ed0de06bae479d63212ed0
https://pubmed.ncbi.nlm.nih.gov/18353996
https://pubmed.ncbi.nlm.nih.gov/18353996
Autor:
Paul J. Deutsch, Gregory A. Winchell, Sheng Bi, Michael Hesney, Julie A. Stone, Kenneth C. Lasseter, Goutam C. Mistry, Elizabeth Migoya, Susan X. Li, Stacy C. Dilzer
Publikováno v:
Journal of clinical pharmacology. 47(8)
This report investigated safety and dosing recommendations of intravenous caspofungin in hepatic insufficiency. In the single-dose study, 8 patients each with mild and moderate hepatic insufficiency received 70 mg of caspofungin. In the multiple-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48c2e286ce61851831c47efe1e06650
https://pubmed.ncbi.nlm.nih.gov/17660480
https://pubmed.ncbi.nlm.nih.gov/17660480
Autor:
Caroline Cilissen, Wen-Lin Luo, Goutam C. Mistry, Arthur J. Bergman, Michael J. Davies, Keith Gottesdiener, Gary A. Herman, John A. Wagner, Wouter Haazen
Publikováno v:
Journal of clinical pharmacology. 47(2)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an incretin enhancer that is approved for the treatment of type 2 diabetes. Sitagliptin is mainly renally eliminated and not a potent inhibitor of CYP450 enzymes in vitro. Rosiglitazone, a thiazolid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c465a7dbef1a61d2c8f8422e782a19c
https://pubmed.ncbi.nlm.nih.gov/17244766
https://pubmed.ncbi.nlm.nih.gov/17244766
Publikováno v:
Journal of clinical pharmacology. 39(6)
The effect of multiple doses of indinavir on the pharmacokinetics of a single dose of theophylline was investigated in 16 healthy male subjects using a randomized, double-blind, placebo-controlled, parallel-group study design. On days 1 and 7, all of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e51b1007bb3c58fbb6346447cb7b22
https://pubmed.ncbi.nlm.nih.gov/10354968
https://pubmed.ncbi.nlm.nih.gov/10354968